Cambiar Investors LLC Has $14.23 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Cambiar Investors LLC increased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,213 shares of the medical research company's stock after buying an additional 9,651 shares during the period. Cambiar Investors LLC owned about 0.12% of Charles River Laboratories International worth $14,234,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CRL. Wetherby Asset Management Inc. grew its holdings in Charles River Laboratories International by 2.5% in the first quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company's stock valued at $509,000 after purchasing an additional 44 shares during the period. Itau Unibanco Holding S.A. grew its holdings in Charles River Laboratories International by 6.2% in the second quarter. Itau Unibanco Holding S.A. now owns 834 shares of the medical research company's stock valued at $175,000 after purchasing an additional 49 shares during the period. Raymond James Trust N.A. grew its holdings in Charles River Laboratories International by 4.8% in the second quarter. Raymond James Trust N.A. now owns 1,117 shares of the medical research company's stock valued at $235,000 after purchasing an additional 51 shares during the period. Toroso Investments LLC grew its holdings in Charles River Laboratories International by 4.8% in the third quarter. Toroso Investments LLC now owns 1,141 shares of the medical research company's stock valued at $225,000 after purchasing an additional 52 shares during the period. Finally, BOKF NA grew its holdings in Charles River Laboratories International by 0.9% in the second quarter. BOKF NA now owns 6,047 shares of the medical research company's stock valued at $1,271,000 after purchasing an additional 54 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 1.0 %

NYSE:CRL traded up $2.44 during mid-day trading on Friday, reaching $253.10. The stock had a trading volume of 529,686 shares, compared to its average volume of 456,211. The company has a market capitalization of $13.04 billion, a price-to-earnings ratio of 27.48, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The stock's 50 day simple moving average is $249.73 and its two-hundred day simple moving average is $218.46. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company's revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period last year, the firm earned $2.98 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRL. Argus boosted their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. TheStreet upgraded shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Guggenheim downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an "outperform" rating in a report on Thursday, February 15th. Finally, UBS Group boosted their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of "Moderate Buy" and a consensus price target of $253.23.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Victoria L. Creamer sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last ninety days. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).